CN110290799A - 用于治疗肺部炎性病症的方法 - Google Patents

用于治疗肺部炎性病症的方法 Download PDF

Info

Publication number
CN110290799A
CN110290799A CN201780086292.7A CN201780086292A CN110290799A CN 110290799 A CN110290799 A CN 110290799A CN 201780086292 A CN201780086292 A CN 201780086292A CN 110290799 A CN110290799 A CN 110290799A
Authority
CN
China
Prior art keywords
asthma
defensins
lung
defensin
hbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780086292.7A
Other languages
English (en)
Chinese (zh)
Inventor
P·诺德基尔德
S·基亚罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Defensin Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Defensin Therapeutics ApS filed Critical Defensin Therapeutics ApS
Publication of CN110290799A publication Critical patent/CN110290799A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780086292.7A 2016-12-13 2017-12-13 用于治疗肺部炎性病症的方法 Pending CN110290799A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670991 2016-12-13
DKPA201670991 2016-12-13
PCT/EP2017/082535 WO2018108971A2 (en) 2016-12-13 2017-12-13 Methods for treating inflammatory conditions of the lungs

Publications (1)

Publication Number Publication Date
CN110290799A true CN110290799A (zh) 2019-09-27

Family

ID=61024712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780086292.7A Pending CN110290799A (zh) 2016-12-13 2017-12-13 用于治疗肺部炎性病症的方法

Country Status (13)

Country Link
US (2) US11413328B2 (cg-RX-API-DMAC7.html)
EP (1) EP3554532B1 (cg-RX-API-DMAC7.html)
JP (2) JP2020512287A (cg-RX-API-DMAC7.html)
KR (1) KR20190108106A (cg-RX-API-DMAC7.html)
CN (1) CN110290799A (cg-RX-API-DMAC7.html)
AU (1) AU2017376400A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019011844A2 (cg-RX-API-DMAC7.html)
CA (1) CA3045079A1 (cg-RX-API-DMAC7.html)
ES (1) ES2994381T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019006848A (cg-RX-API-DMAC7.html)
RU (1) RU2019120956A (cg-RX-API-DMAC7.html)
SG (1) SG10202012106WA (cg-RX-API-DMAC7.html)
WO (1) WO2018108971A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113262297A (zh) * 2020-11-02 2021-08-17 中南大学湘雅二医院 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用
CN113521047A (zh) * 2021-08-23 2021-10-22 新疆医科大学第四附属医院 丁酸盐在制备慢性阻塞性肺疾病药物中的应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화
CN108815199B (zh) * 2018-08-03 2021-10-01 南华大学 鼠衣原体在制备抗溃疡性结肠炎药物中的应用
US11331269B2 (en) * 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
KR102742007B1 (ko) 2018-10-09 2024-12-12 유니버시티 오브 서던 캘리포니아 양이온성 마크로사이클릭 펩티드의 전신 전달성, 내약성, 및 효능을 향상시키기 위한 조성물 및 방법(compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides)
JP7479381B2 (ja) * 2019-01-07 2024-05-08 アエスクルス バイオ エーピーエス 治療または予防に使用するためのディフェンシン断片
WO2020182970A1 (en) * 2019-03-14 2020-09-17 Om Pharma Sa Process for making stable bacterial extracts and their use as pharmaceuticals
US12472231B2 (en) 2020-03-18 2025-11-18 The University Of Hong Kong Compositions of anti-viral peptides and methods of use thereof
EP4457237A4 (en) * 2021-12-27 2025-11-12 Versitech Ltd ANTIVIRAL PEPTIDES AND THEIR METHODS OF USE
CN121360148B (zh) * 2025-12-18 2026-06-30 白山市林源春生态科技股份有限公司 一种经特定发酵获得的太岁分子生态液提取物及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060036083A1 (en) * 2002-02-19 2006-02-16 Joel Moss Modified defensins and their use
CN102159232A (zh) * 2008-07-18 2011-08-17 诺维信阿德宁生物技术公司 使用哺乳动物β防御素治疗炎性疾病
US20120164123A1 (en) * 2009-09-10 2012-06-28 Human Services Method for the treatment of pulmonary disease and method of producing proteins of use therein
US20130052213A1 (en) * 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
US20130281361A1 (en) * 2010-11-08 2013-10-24 Pulmatrix, Inc. Methods of treating and preventing rhinovirus infection
CN104981479A (zh) * 2012-12-06 2015-10-14 品诺制药公司 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
CA2841097A1 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20040091498A1 (en) 2002-05-31 2004-05-13 Aaron Diamond Aids Research Center Defensins: use as antiviral agents
GB0521139D0 (en) * 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US7528107B2 (en) 2005-11-30 2009-05-05 Auburn University Methods of treating inflammation in mammalian tissues comprising administering human alpha-defensins
WO2008115390A2 (en) 2007-03-16 2008-09-25 The Hamner Institutes For Health Sciences Methods of using defensins to treat diabetes
LT2237799T (lt) 2008-02-01 2019-07-25 Ascendis Pharma A/S Provaistas, apimantis besiskaidantį linkerį
CN102159233A (zh) 2008-07-18 2011-08-17 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
US8410049B2 (en) 2009-10-28 2013-04-02 Cebix Methods and kits for preventing hypoglycemia
KR101320472B1 (ko) * 2010-06-16 2013-10-23 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
JP6219277B2 (ja) 2011-07-08 2017-10-25 ディフェンシン セラピューティクス アンパルトセルスカブDefensin Therapeutics Aps 炎症性腸疾患の経口治療
US9464124B2 (en) * 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20200095472A (ko) * 2017-11-10 2020-08-10 디펜신 테라퓨틱스 에이피에스 조산아에서의 점막 방어 및 장/폐 기능의 성숙화

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060036083A1 (en) * 2002-02-19 2006-02-16 Joel Moss Modified defensins and their use
CN102159232A (zh) * 2008-07-18 2011-08-17 诺维信阿德宁生物技术公司 使用哺乳动物β防御素治疗炎性疾病
US20120164123A1 (en) * 2009-09-10 2012-06-28 Human Services Method for the treatment of pulmonary disease and method of producing proteins of use therein
US20130281361A1 (en) * 2010-11-08 2013-10-24 Pulmatrix, Inc. Methods of treating and preventing rhinovirus infection
US20130052213A1 (en) * 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide
CN104981479A (zh) * 2012-12-06 2015-10-14 品诺制药公司 用免疫抑制性Tat衍生多肽治疗炎症、自身免疫和神经退行性疾病

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113262297A (zh) * 2020-11-02 2021-08-17 中南大学湘雅二医院 一种基于巴氏菌的治疗性肺癌疫苗及其配置方法和应用
CN113521047A (zh) * 2021-08-23 2021-10-22 新疆医科大学第四附属医院 丁酸盐在制备慢性阻塞性肺疾病药物中的应用

Also Published As

Publication number Publication date
JP2020512287A (ja) 2020-04-23
US20230067261A1 (en) 2023-03-02
US20190336576A1 (en) 2019-11-07
EP3554532B1 (en) 2024-09-25
CA3045079A1 (en) 2018-06-21
AU2017376400A1 (en) 2019-06-20
WO2018108971A3 (en) 2018-07-26
RU2019120956A (ru) 2021-01-15
EP3554532A2 (en) 2019-10-23
BR112019011844A2 (pt) 2022-05-10
KR20190108106A (ko) 2019-09-23
ES2994381T3 (en) 2025-01-23
MX2019006848A (es) 2019-10-07
JP2025013922A (ja) 2025-01-28
SG10202012106WA (en) 2021-01-28
RU2019120956A3 (cg-RX-API-DMAC7.html) 2021-04-13
US11413328B2 (en) 2022-08-16
WO2018108971A2 (en) 2018-06-21
EP3554532C0 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US20230067261A1 (en) Methods for treating inflammatory conditions of the lungs
US20250009844A1 (en) Maturation of mucosal defense and gut/lung function in the preterm infant
JP6001151B2 (ja) 顆粒球マクロファージコロニー刺激因子を投与することによる肺の宿主防御の増強
KR20110044863A (ko) 포유류 베타 방어소를 이용한 염증성 장질환의 치료
JP2011225596A (ja) 哺乳動物のベータ・ディフェンシンを用いた、炎症性腸疾患の治療
CN103429610A (zh) 用于抑制炎症的肽
JP4537956B2 (ja) 喘息治療剤
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
WO2012064601A1 (en) Methods of treating and preventing rhinovirus infection
US20150174204A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
JP7545893B2 (ja) 難治性非結核性マイコバクテリア感染症の治療のためのgm-csf
WO2015110536A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment and prevention of severe forms of bronchial asthma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220322

Address after: Denmark bagsvaerd

Applicant after: NOVOZYMES A/S

Address before: Copenhagen, Denmark

Applicant before: DEFENSIN THERAPEUTICS APS

TA01 Transfer of patent application right